Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Fournier, Philippe ^a   Arnold, A ^a   Schirrmacher, V ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antitumor immunity; DC maturation and activation; DC based therapy; IFN ; IL 10 and 12; RIG I

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; CELL SURFACE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INTERFERON INDUCTION; MONOCYTE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; POLARIZATION; TH1 CELL; VIRUS GENE; VIRUS INFECTION;

ANIMALS; DENDRITIC CELLS; DNA, COMPLEMENTARY; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; MONOCYTES; NEOPLASMS; NEWCASTLE DISEASE VIRUS; POLYMERASE CHAIN REACTION; RNA;

EID: 70350049934     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (87)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245.
2. Wilson NS, El Sukkari D, Belz GT et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 2003; 102: 2187.
3. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class 1 products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 1627-1638. (Pubitemid 36026474)
4. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779. (Pubitemid 32983013)
5. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002; 196: 1079-1090. (Pubitemid 35231766)
6. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108: 1435-1440. (Pubitemid 44316106)
7. Steinman, RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411-416. (Pubitemid 30693565)
8. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
9. Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem 2007; 282: 15319-15323.
10. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137. (Pubitemid 43135878)
11. Moore CB, Ting JP. Regulation of mitochondrial antiviral signaling pathways. Immunity 2008; 28: 735-739. (Pubitemid 351778413)
12. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737. (Pubitemid 39023305)
13. Hornung V, Ellegast J, Kim S et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314: 994-997.
14. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143: 1-20.
15. Biron CA. Initial and innate responses to viral infections: pattern setting in immunity or disease. Curr Opin Microbiol 1999; 2: 374-381.
16. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002; 14: 432-436. (Pubitemid 34671244)
17. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995. (Pubitemid 41057715)
18. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6: 476-483.
19. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306. (Pubitemid 40516155)
20. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-150. (Pubitemid 350045575)
21. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005; 17: 163-169. (Pubitemid 40343103)
22. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-147. (Pubitemid 36287518)
23. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008; 99: 363-407.
24. Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008; 60: 173-183.
25. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8: 51-66.
26. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6: 1163-1167.
27. Schirrmacher V, Fournier P. Newcastle Disease Virus: a promising vector for viral therapy of cancer In: Harrington KJ, Pandha HS, Vile RG (Eds): Viral Therapy of Cancer. Wiley Publishers, 2008 (ISBN: 978-0-470-01922-1).
28. Schirrmacher V, Fournier P (Eds). Newcastle Disease Virus: A promising vector for viral therapy, immune therapy and gene therapy of cancer. Cancer Gene Therapy (2nd edn). Methods in Molecular Medicine. The Humana Press Inc, 2008.
29. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009; 58: 61-69.
30. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol 2009; 34: 971-982.
31. Diebold SS. Activation of dendritic cells by toll-like receptors and C-type lectins. Handb Exp Pharmacol 2009; 188: 3-30.
32. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383.
33. López CB, Fernandez-Sesma A, Czelusniak SM, Schulman JL, Moran TM. A mouse model for immunization with ex vivo virus-infected dendritic cells. Cell Immunol 2000; 206: 107-115. (Pubitemid 32121623)
34. Juang YT, Au WC, Lowther W, Hiscott J, Pitha PM. Lipopolysaccharide inhibits virus-mediated induction of interferon genes by disruption of nuclear transport of interferon regulatory factors 3 and 7. J Biol Chem 1999; 274: 18060-18066. (Pubitemid 129519172)
35. López CB, García-Sastre A, Williams BR, Moran TM. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 2003; 187: 1126-1136. (Pubitemid 36399354)
36. Honda K, Sakaguchi S, Nakajima C et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 2003; 100: 10872-10877. (Pubitemid 37140120)
37. López CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004; 173: 6882-6889. (Pubitemid 39541075)
38. Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28. (Pubitemid 41019654)
39. Kumagai Y, Kumar H, Koyama S, Kawai T, Takeuchi O, Akira S. TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-α production in plasmacytoid dendritic cells. J Immunol 2009; 182: 3960-3964.
40. Yoneyama M, Kikuchi M, Matsumoto K et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-2858. (Pubitemid 41170502)
41. Lopez CB, Yount JS, Moran TM. Toll-like receptor-independent triggering of dendritic cell maturation by viruses. J Virol 2006; 80: 3128-3134.
42. Rani MR, Ransohoff RM. Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression. J Interferon Cytokine Res 2005; 25: 788-798. (Pubitemid 43068490)
43. Schwartz RH, Mueller DL. Immunological tolerance. In: Paul WE (Ed): Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins, 2003, pp 901-934.
44. Iezzi G, Scheidegger D, Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med 2001; 193: 987-993. (Pubitemid 32525872)
45. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
46. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
47. Heufler C, Koch K, Stanzl U et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-α production by T helper 1 cells. Eur J Immunol 1996; 26: 659-668. (Pubitemid 26091397)
48. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58. (Pubitemid 47413194)
49. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003; 19: 641-644. (Pubitemid 37490789)
50. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166: 4312-4318. (Pubitemid 32233711)
51. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229-1235. (Pubitemid 27197228)
52. Fukao T, Frucht DM, Yap G, Gadina M, O'Shea JJ, Koyasu S. Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol 2001; 166: 4446-4455. (Pubitemid 32233728)
53. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445.
54. Ladányi A, Somlai B, Gilde K, Fejös Z, Gaudi I, Tímár J. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10: 521-530. (Pubitemid 38173990)
55. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964. (Pubitemid 44498003)
56. Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69: 2685-2693.
57. Grauer O, Pöschl P, Lohmeier A, Adema GJ, Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-B2. J Neurooncol 2007; 82: 151-161. (Pubitemid 46431857)
58. Bordería AV, Hartmann BM, Fernandez-Sesma A, Moran TM, Sealfon SC. Antiviral-activated dendritic cells: a paracrine-induced response state. J Immunol 2008; 181: 6872-6881.
59. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25: 500-508.
60. Thurner B, Haendle I, Röder C et al. Vaccination with Mage3A1 peptide-pulsed mature, monocyte derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678. (Pubitemid 30002348)
61. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288. (Pubitemid 34564330)
62. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2: 1010-1017. (Pubitemid 33069495)
63. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004; 199: 1607-1618. (Pubitemid 38821994)
64. Menges M, Rössner S, Voigtländer C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195: 15-21. (Pubitemid 34074492)
65. Spörri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005; 6: 163-170.
66. Hou B, Reizis B, Defranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 2008; 29: 272-282.
67. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227: 234-247.
68. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003; 197: 1141-1151.
69. Hernandez J, Aung S, Marquardt K, Sherman LA. Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens. J Exp Med 2002; 196: 323-333. (Pubitemid 34875662)
70. de Jong, EC, Vieira PL, Kalinski P et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002; 168: 1704-1709. (Pubitemid 34135767)
71. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-776. (Pubitemid 43090462)
72. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842-1852. (Pubitemid 46383411)
73. Ahmed M, Mitchell LM, Puckett S, Brzoza-Lewis KL, Lyles DS, Hiltbold EM. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J Virol 2009; 83: 2962-2975.
74. Ahmed M, Brzoza KL, Hiltbold EM. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006; 80: 2194-2205. (Pubitemid 43271526)
75. López CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 2004; 173: 6882-6889. (Pubitemid 39541075)
76. Errington F, Steele L, Prestwich R et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008; 180: 6018-6026.
77. Ueda Y, Hasegawa M, Yonemitsu Y. Sendai virus for cancer immunotherapy. Methods Mol Biol 2009; 515: 299-308.
78. Tatsuta K, Tanaka S, Tajiri T et al. Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther 2009; 16: 240-251.
79. Yonemitsu Y, Ueda Y, Kinoh H, Hasegawa M. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Front Biosci 2008; 13: 4953-4959. (Pubitemid 351599649)
80. Shibata S, Okano S, Yonemitsu Y et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol 2006; 177: 3564-3576. (Pubitemid 44359887)
81. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623-3633. (Pubitemid 43121851)
82. Maker AV, Yang JC, Sherry RM et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29: 455-463.
83. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008; 68: 5972-5978.
84. Poeck H, Besch R, Maihoefer C et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14: 1256-1263.
85. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5: 112-124.
86. Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 2005; 101: 12-17. (Pubitemid 41297493)
87. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002; 21: 685-694.